MedPath

A Non-interventional Prospective Study of Early HER2-negative High-risk Breast Cancer and BRCA1/2 Mutations Prevalence in RussiA

Active, not recruiting
Conditions
Breast Cancer
Registration Number
NCT05939128
Lead Sponsor
AstraZeneca
Brief Summary

(Neo)adjuvant treatment approaches and outcomes

Detailed Description

Not available

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
625
Inclusion Criteria
  • Patients aged ≥ 18 years old

    -. Signed ICF, including patient's consent for genetic testing specimens from primary tumor and blood samples

  • Early HER2-negative BC (stages 2 and 3)

  • Compliance with at least 1 of the criteria for BRCA1/2 testing in accordance with the clinical guidelines of the Ministry of Health of the Russian Federation

  • Unknown BRCAm status or negative BRCAm PCR test

  • Performed surgical treatment (not more than 7 months before inclusion)

    -. High risk of recurrence according to one or more criteria:

    1. incomplete pathomorphological response (in case of neoadjuvant therapy)
    2. CPS-EG 3 scale score 3 and more (in case of neoadjuvant therapy)
    3. presence of ≥ 4 metastatic lymph nodes in HR+ pts (in case of only adjuvant therapy)
    4. ≥pT2 or ≥pN1 in TNBC pts (in case of only adjuvant therapy)
    5. Any other high risk criterion according to investigators opinion
  • The presence of postoperative or biopsy FFPE

Exclusion Criteria
  • Participation in another clinical study with an investigational product during the last 3 months
  • Confirmation that the subject was already included in this study before
  • Absence of a written informed consent form; Data erroneously collected from subjects for which written consent is not available, will not be included in or will be deleted from the study database

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The primary objective of this study is to determine the prevalence of germline and somatic BRCA1/2 mutations in high-risk early HER2-negative breast cancer3 years

The prevalence of germline and somatic BRCA1/2 mutations in high-risk early HER2-negative breast cancer will be presented as a number of missing and non-missing records, median, standard deviation, 95% confidence interval for median

Secondary Outcome Measures
NameTimeMethod
To describe treatment approaches of high-risk early HER2-negative breast cancer in routine practice in the general population, in the BRCAm and non-BRCAm population3 years

Demographics, clinical characteristics, and treatment approaches will be summarized using descriptive statistics.

To determine invasive disease-free survival for high-risk early HER2-negative breast cancer in the general population, in the BRCAm and non-BRCAm population3 years

The Kaplan-Meier method will be used to estimate the median (95% CI) IDFS and OS for the total sample and all subgroups. Cumulative survival curves will be created using Kaplan-Meier analysis

To determine 3-year OS for high-risk early HER2-negative breast cancer in the general population, in the BRCAm and non-BRCAm population3 years

The Kaplan-Meier method will be used to estimate the median (95% CI) IDFS and OS for the total sample and all subgroups. Cumulative survival curves will be created using Kaplan-Meier analysis

To determine the prevalence of HRR mutations in HER2-negative breast cancer3 years

Testing the archived tumour specimen and blood for BRCA1/2m and HRRm status

To determine invasive disease-free survival in the HRRm population (including BRCA1/2)3 years

Testing the archived tumour specimen and blood for BRCA1/2m and HRRm status

To evaluate concordance between P53 expression and BRCAm3 years

Testing the archived tumour specimen and blood

To assess the quality of life in patients with various types of adjuvant systemic therapy3 years

completed WHOQOL-BREF questionnaire will be assessed

Trial Locations

Locations (1)

Research Site

🇷🇺

Yaroslavl, Russian Federation

Research Site
🇷🇺Yaroslavl, Russian Federation

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.